Condition: Breast Cancer · Breast Cancer Early Stage Breast Cancer (Stage 1-3) · Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Randomized trial that compares a personalized digitally-enabled pathway delivered by a mobile application in addition to standard of care vs. standard of care alone in patients with HR+ early breast cancer reporting endocrine therapy related adverse events. The HOPE study is a national, prospective, randomized, open-label trial conducted in France. 180 patients will be randomly assigned 1:1 to receive either 12 weeks of multimodal Resilience© digital companion including education and self-care modules in addition to the standard of care provided by their treating oncologists and supportive care team at their care centers or 12 weeks of standard of care provided by their treating oncologists and supportive care team at their care centers. Data from the literature in oncology trials with Patient-Reported Outcomes suggests that in the absence of double-blind concealment, clinically important differences could still be detected.
This description comes directly from the study's public registry record.
Maria Alice FRANZOI, MD · +33142114211 · Mariaalice.BORINELLI-FRANZOI@gustaveroussy.fr
Chloé Serhal, PhD · +33142114211 · Chloé.serhal@gustaveroussy.fr
Always discuss trial participation with your own doctor first.
| Gustave Roussy | Villejuif, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06781996